Larger studies that overcome limitations of heterogeneity across studies and a relatively infrequent occurrence of complications are required to determine the optimal medium for loss of resistance during epidural block.

This paper is dedicated to the statistical analysis of the chaos, generated by Rössler attractor, based on the socalled "Degenerated Cumulant Equations" method. The approach is illustrated by the calculus of the first cumulants, which are necessary to create an approximation of the Probability Density Function (PDF), applying the Gramm-Charlier series, the model distribution method, etc. An approximate method for the variance calculation at the output of the Rössler strange attractor is presented as well. The latter is based on the Kolmogorov-Sinai entropy estimated by the Lyapunov exponents for a statistically linearized chaotic system. Finally, an application using Rössler attractor output signals to model Radio Frequency Interferences (RFI) provided by Peripherical Component Interface express (PCIe) serial bus of high speed interconnects of Laptops and Desktops is presented.

This study suggests that there is no difference in managing postoperative pain and swelling with betamethasone versus betamethasone and ketorolac.

No abstract

<p>Supplementary Data, Materials and Methods</p>

<div>Abstract<p><b>Purpose:</b> Triple-negative breast cancer (TNBC) and ovarian cancer each comprise heterogeneous tumors, for which current therapies have little clinical benefit. Novel therapies that target and eradicate tumor-initiating cells (TIC) are needed to significantly improve survival.</p><p><b>Experimental Design:</b> A panel of well-annotated patient-derived xenografts (PDX) was established, and surface markers that enriched for TIC in specific tumor subtypes were empirically determined. The TICs were queried for overexpressed antigens, one of which was selected to be the target of an antibody–drug conjugate (ADC). The efficacy of the ADC was evaluated in 15 PDX models to generate hypotheses for patient stratification.</p><p><b>Results:</b> We herein identified E-cadherin (CD324) as a surface antigen able to reproducibly enrich for TIC in well-annotated, low-passage TNBC and ovarian cancer PDXs. Gene expression analysis of TIC led to the identification of Ephrin-A4 (EFNA4) as a prospective therapeutic target. An ADC comprising a humanized anti-EFNA4 monoclonal antibody conjugated to the DNA-damaging agent calicheamicin achieved sustained tumor regressions in both TNBC and ovarian cancer PDX <i>in vivo</i>. Non-claudin low TNBC tumors exhibited higher expression and more robust responses than other breast cancer subtypes, suggesting a specific translational application for tumor subclassification.</p><p><b>Conclusions:</b> These findings demonstrate the potential of PF-06647263 (anti–EFNA4-ADC) as a first-in-class compound designed to eradicate TIC. The use of well-annotated PDX for drug discovery enabled the identification of a novel TIC target, pharmacologic evaluation of the compound, and translational studies to inform clinical development. <i>Clin Cancer Res; 21(18); 4165–73. ©2015 AACR</i>.</p></div>

<div>Abstract<p><b>Purpose:</b> Triple-negative breast cancer (TNBC) and ovarian cancer each comprise heterogeneous tumors, for which current therapies have little clinical benefit. Novel therapies that target and eradicate tumor-initiating cells (TIC) are needed to significantly improve survival.</p><p><b>Experimental Design:</b> A panel of well-annotated patient-derived xenografts (PDX) was established, and surface markers that enriched for TIC in specific tumor subtypes were empirically determined. The TICs were queried for overexpressed antigens, one of which was selected to be the target of an antibody–drug conjugate (ADC). The efficacy of the ADC was evaluated in 15 PDX models to generate hypotheses for patient stratification.</p><p><b>Results:</b> We herein identified E-cadherin (CD324) as a surface antigen able to reproducibly enrich for TIC in well-annotated, low-passage TNBC and ovarian cancer PDXs. Gene expression analysis of TIC led to the identification of Ephrin-A4 (EFNA4) as a prospective therapeutic target. An ADC comprising a humanized anti-EFNA4 monoclonal antibody conjugated to the DNA-damaging agent calicheamicin achieved sustained tumor regressions in both TNBC and ovarian cancer PDX <i>in vivo</i>. Non-claudin low TNBC tumors exhibited higher expression and more robust responses than other breast cancer subtypes, suggesting a specific translational application for tumor subclassification.</p><p><b>Conclusions:</b> These findings demonstrate the potential of PF-06647263 (anti–EFNA4-ADC) as a first-in-class compound designed to eradicate TIC. The use of well-annotated PDX for drug discovery enabled the identification of a novel TIC target, pharmacologic evaluation of the compound, and translational studies to inform clinical development. <i>Clin Cancer Res; 21(18); 4165–73. ©2015 AACR</i>.</p></div>

No abstract